Orchid Pharma Q4 FY26 earnings call

Orchid Pharma is transitioning from a recovery phase to platform creation, aiming to build a differentiated anti-infectives platform. This strategy encompasses innovation, key starting materials, APIs, FDFs, and antimicrobial stewardship capabilities, supported by investments in fermentation and protein synthesis research. The long-term objective is to become one of the few integrated sterile Cephalosporin companies globally, spanning the entire value chain from manufacturing to commercialization.

The company reported a stable Q4 FY26 with standalone revenue of INR238 crores, consistent with INR237 crores in Q4 FY25, and EBITDA of INR42.3 crores, up from INR40 crores in Q4 FY25. However, FY26 was challenging, with standalone revenue declining to INR811 crores from INR922 crores in FY25, and EBITDA falling to INR101 crores from INR155 crores in FY25. This decline was primarily due to significant pricing and volume pressures in the global antibiotic industry, though gross margins showed signs of recovery in Q4.

Exblifep, a key differentiated product, is in early commercialization in India and Europe, demonstrating a fourfold improvement in Q1 sales over the previous quarter. Orchid Pharma is actively pursuing licensing opportunities in the US, Russia, Latin America, and Southeast Asia, with lifetime sales projected at $1 billion to $2 billion over the patent life. The company anticipates peak sales to be reached in the 4th or 5th year post-launch, a revision from the earlier three-year projection, though definitive agreements for these deals are taking longer than expected.

The Cefiderocol facility is on track for commissioning by the end of calendar year 2026, with product launch anticipated in Q2 or Q3 calendar year 2027, pending regulatory approvals. The Antimicrobial Stewardship (AMS) platform continues to grow and gain recognition in hospitals, despite currently being an annual EBITDA drag of approximately INR8 crores. This platform is considered strategically important for positioning Orchid as a long-term participant in anti-infective healthcare solutions and provides a strong market entry point for products like Cefiderocol.

As the only Indian sterile Cephalosporin manufacturer with a US FDA-approved facility, Orchid Pharma plans to invest further in fill, finish, and formulation capabilities at the same site. The objective is to launch five to six large sterile products, targeting approximately two-thirds of the $1.2 billion US Cephalosporin market. The US business is expected to become a significant contributor to both top and bottom lines over the next five years, with a strategy to file ANDAs initially through CMOs to de-risk and accelerate market entry.

The merger with Dhanuka Laboratories is awaiting a formal written order after the March hearing, with expectations for it to be received shortly. This merger is projected to contribute 1% to 2% EBITDA margin expansion through synergies and operational efficiencies. The 7ACA project remains on track for commissioning in Q1 calendar year 2027, though execution is described as a 'race against time.' The company plans to utilize 75% of 7ACA in-house for downstream products, expecting an additional 5% EBITDA from these products.

While Q4 saw some recovery in gross margins, the overall pricing environment remains volatile due to geopolitical factors and supply chain costs. The company acknowledged the challenge of passing on increased input costs in a competitive industry. Orchid Pharma has focused on productivity, operational efficiency, and cost discipline, successfully reducing costs across various operating heads, including power, fuel, and finance costs, despite inflationary pressures and strategic investments.